Relypsa's patiromer under FDA review; shares jump
This article was originally published in Scrip
Executive Summary
Shares of Relypsa jumped 7.8% on 15 December after the company said the FDA has accepted for review the new drug application (NDA) for patiromer, a high capacity, oral potassium binder, for oral suspension as a treatment for hyperkalemia, a serious condition caused by abnormally elevated levels of potassium in the blood.